On October 20, 2020 Nature Technology Corporation, a leading developer and provider of non-viral vectors, technologies and services for advancing gene and cell therapy and immunotherapy, reported that Deborah Moorad-Watts, formerly Chief Business Officer, has been appointed Chief Executive Officer of the Company (Press release, Nature Technology, OCT 20, 2020, View Source [SID1234568704]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Commenting on today’s announcement, Ms. Moorad-Watts stated, "I am honored to accept the role of Chief Executive Officer and look forward to helping guide NTC in its mission to improve the effectiveness, safety, availability and economy of gene-based medicines. NTC has a proud history of innovating and redefining the promise and potential of nucleic acids-based drugs, manufacturing, and I’m proud to continue and expand on that legacy."
Former CEO and now President and Executive Chairman of the Board, Clague P. Hodgson, PhD, said, "As a founder of the company, I believe that Deborah’s experience, knowledge and dedication will help NTC continue to grow and lead in a field that is making such an important difference in the lives of the patients we all ultimately serve. We are pleased to have her in this new role."
Ms. Moorad-Watts has extensive experience managing diverse business portfolios and strategic efforts for further advancing technologies leading to licensure and/or M&A activities. Her areas of expertise include global sales & marketing, clinical manufacturing, gene and cell therapy, mergers and acquisitions, GMP business development, R&D, contract negotiation, KOL engagement, licensing, and more.
She has led product commercialization efforts from concept through launch, for both start-ups and fortune 500 companies. She has also managed intellectual property and licensing strategy with pharmaceutical and medical device companies across the world, including the launch and management of an investigational drug for glioblastoma.